Immunogen Inc Quick Ratio (IMGN) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Immunogen inc   (NASDAQ: IMGN)

Immunogen Inc 's Quick Ratio

IMGN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 4.5 below Immunogen Inc average.

Within Major Pharmaceutical Preparations industry 235 other companies have achieved higher Quick Ratio than Immunogen Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 426 to 974.

Explain Quick Ratio?
How much Cash & cash equivalents IMGN´s has?
What are IMGN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IMGN/financial-strength
https://api.csimarket.com/api/v1/companies/IMGN/fundamentals
https://api.csimarket.com/api/v1/companies/IMGN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
IMGN Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2 		(Mar 31 2023)
Q1 		(Dec 31 2022)
Q4 		(Sep 30 2022)
Q3
Y / Y Current Liabilities Change 29.93 %
Y / Y Cash & cash equivalent Change 95.64 %
Quick Ratio MRQ 4.5
IMGN's Total Ranking # 974
Seq. Current Liabilities Change 43.71 %
Seq. Cash & cash equivalent Change 5.87 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 236
Healthcare Sector # 400
Overall Market # 974


Quick Ratio Statistics
High Average Low
21.73 6.57 1.89
(Mar 31 2013)   (Sep 30 2020)




Financial Statements
Immunogen Inc 's Current Liabilities $ 135 Millions Visit IMGN's Balance sheet
Immunogen Inc 's Cash & cash equivalent $ 606 Millions Visit IMGN's Balance sheet
Source of IMGN's Sales Visit IMGN's Sales by Geography


Cumulative Immunogen Inc 's Quick Ratio

IMGN's Quick Ratio for the trailling 12 Months

IMGN Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months 		(Mar 31 2023)
12 Months 		(Dec 31 2022)
12 Months 		(Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 20.24 %
Y / Y Cash & cash equivalent TTM Growth 3.38 %
Quick Ratio TTM 3.66
Total Ranking TTM # 417
Seq. Current Liabilities TTM Growth 7.37 %
Seq. Cash & cash equivalent TTM Growth 21.8 %

Quick ratio ranking by company, industry and sector >> Back to IMGN Financial Strength Comparisons >> Go to Compare IMGN Quick Ratio to its Competitors

On the trailing twelve months basis IMGN Cash & cash equivalent soared by 95.64 % in Q3 2023 year on year, faster than Current Liabilities, this led to increase in in Immunogen Inc 's Quick Ratio to 3.66, Quick Ratio remained below IMGN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 512 other companies have achieved higher Quick Ratio than Immunogen Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3577 to 3668.

Explain Quick Ratio?
How much Cash & cash equivalents IMGN´s has?
What are IMGN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 513
Healthcare Sector # 1031
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
12.88 5.29 2.11
(Mar 31 2013)   (Jun 30 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Compass Pathways Plc  12.36 $ 248.369  Millions$ 20.100  Millions
Biomea Fusion Inc   12.28 $ 199.090  Millions$ 16.210  Millions
Ligand Pharmaceuticals Incorporated  12.11 $ 190.502  Millions$ 15.727  Millions
Oric Pharmaceuticals Inc   12.00 $ 227.296  Millions$ 18.944  Millions
Anebulo Pharmaceuticals Inc   11.89 $ 8.521  Millions$ 0.717  Millions
Ovid Therapeutics Inc   11.70 $ 87.072  Millions$ 7.439  Millions
Xortx Therapeutics inc   11.69 $ 3.448  Millions$ 0.295  Millions
Sensei Biotherapeutics Inc   11.57 $ 72.013  Millions$ 6.226  Millions
Protagonist Therapeutics inc   11.51 $ 320.751  Millions$ 27.867  Millions
Ventyx Biosciences Inc   11.48 $ 300.819  Millions$ 26.208  Millions
Indaptus Therapeutics Inc   11.30 $ 15.964  Millions$ 1.413  Millions
Cormedix Inc   11.29 $ 86.587  Millions$ 7.671  Millions
Artelo Biosciences Inc   11.10 $ 10.225  Millions$ 0.921  Millions
Erasca Inc   11.10 $ 296.668  Millions$ 26.730  Millions
Anaptysbio Inc   11.03 $ 413.047  Millions$ 37.437  Millions
Lite Strategy Inc   10.95 $ 82.202  Millions$ 7.509  Millions
Opus Genetics Inc   10.84 $ 42.361  Millions$ 3.909  Millions
Ataibeckley Inc   10.77 $ 208.994  Millions$ 19.403  Millions
Nkarta Inc   10.75 $ 275.613  Millions$ 25.640  Millions
Lipocine Inc   10.64 $ 23.848  Millions$ 2.241  Millions
Kinnate Biopharma Inc   10.62 $ 167.576  Millions$ 15.774  Millions
Lisata Therapeutics Inc   10.60 $ 54.394  Millions$ 5.132  Millions
Pasithea Therapeutics Corp   10.53 $ 19.680  Millions$ 1.869  Millions
Arbutus Biopharma Corp  10.48 $ 241.088  Millions$ 23.015  Millions
Cryoport inc   10.41 $ 467.518  Millions$ 44.905  Millions
Structure Therapeutics Inc   10.22 $ 205.424  Millions$ 20.091  Millions
Actinium Pharmaceuticals Inc  10.18 $ 82.978  Millions$ 8.150  Millions
89bio Inc   9.99 $ 251.926  Millions$ 25.212  Millions
Lianbio  9.84 $ 252.222  Millions$ 25.627  Millions
Dogwood Therapeutics inc   9.82 $ 4.786  Millions$ 0.487  Millions

Date modified: 2026-10-07T00:41:51+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.